Korean Circ J.  2013 Dec;43(12):804-810. 10.4070/kcj.2013.43.12.804.

Incidence and Risk Factors for Early-Onset Hypertension after Allogeneic Hematopoietic Stem Cell Transplantation in Children

• Kwon DH
• Jung S
• Lee EJ
• Lee JY
• Moon S
• Lee JW
• Chung NG
• Cho B
• Kim HK

• KMID: 2224774
• DOI: http://doi.org/10.4070/kcj.2013.43.12.804

Abstract

BACKGROUND AND OBJECTIVES
Survivors of pediatric hematopoietic stem cell transplantation (HSCT) are at risk for developing hypertension. The objectives of this study are to evaluate the prevalence and risk factors of early onset hypertension during the engraftment period after HSCT.
SUBJECTS AND METHODS
This is a retrospective study of 157 consecutive patients (mean age at HSCT: 9.1+/-5.1 years) who underwent HSCT for acute myeloid leukemia (n=47), acute lymphoblastic leukemia (n=43), severe aplastic anemia (n=41), and other reasons (n=26). Blood pressure data were collected at five time points: 0, 7, 14, 21, and 28 days after HSCT. Hypertension was defined as having systolic and/or diastolic blood pressure > or =95th percentile according to age, gender, and height. To analyze the risk factors related to hypertension, data, including patients' demographic and transplant characteristics, were reviewed.
RESULTS
Hypertension developed in 59 patients (38%), among whom 12 (7.6%) required long term therapy. Thirty-two (54%) patients had systolic and diastolic, 8 (14%) had only systolic, and 19 (32%) had only diastolic hypertension. Younger age, acute graft-versus-host disease, sinusoidal obstruction syndrome, treatment with antifungal agent, and greater increase in serum creatinine (Cr) levels were associated with hypertension. Multivariate analysis showed that younger age at HSCT and greater increase in serum Cr level were independent risk factors for hypertension.
CONCLUSION
Prevalence of hypertension during immediate post-HSCT period is high, especially in younger children. A greater increase in Cr after HSCT was significantly associated with hypertension. Further study is needed to elucidate long-term cardiovascular complications in pediatric HSCT survivors.

Keyword

Hematopoletic stem cell transplantation; Child; Incidence; Blood pressure; Hypertension

MeSH Terms

Anemia, Aplastic
Blood Pressure
Child
Creatinine
Graft vs Host Disease
Hematopoietic Stem Cell Transplantation*
Hematopoietic Stem Cells*
Hepatic Veno-Occlusive Disease
Humans
Hypertension*
Incidence*
Leukemia, Myeloid, Acute
Multivariate Analysis
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Prevalence
Retrospective Studies
Risk Factors*
Survivors
Creatinine

Reference

1. Baker KS, Ness KK, Steinberger J, et al. Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study. Blood. 2007; 109:1765–1772.

2. Majhail NS, Challa TR, Mulrooney DA, Baker KS, Burns LJ. Hypertension and diabetes mellitus in adult and pediatric survivors of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2009; 15:1100–1107.

3. Tichelli A, Passweg J, Wójcik D, et al. Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2008; 93:1203–1210.

4. Hoffmeister PA, Hingorani SR, Storer BE, Baker KS, Sanders JE. Hypertension in long-term survivors of pediatric hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2010; 16:515–524.

5. Kist-van Holthe JE, Bresters D, Ahmed-Ousenkova YM, et al. Long-term renal function after hemopoietic stem cell transplantation in children. Bone Marrow Transplant. 2005; 36:605–610.

6. Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension. 2007; 49:69–75.

7. McNiece KL, Poffenbarger TS, Turner JL, Franco KD, Sorof JM, Portman RJ. Prevalence of hypertension and pre-hypertension among adolescents. J Pediatr. 2007; 150:640–644. 644.e1

8. Redwine KM, Acosta AA, Poffenbarger T, Portman RJ, Samuels J. Development of hypertension in adolescents with pre-hypertension. J Pediatr. 2012; 160:98–103.

9. Carretero OA, Oparil S. Essential hypertension. Part I: definition and etiology. Circulation. 2000; 101:329–335.

10. Onusko E. Diagnosing secondary hypertension. Am Fam Physician. 2003; 67:67–74.

11. Kist-van Holthe JE, van Zwet JM, Brand R, van Weel MH, Vossen JM, van der Heijden AJ. Bone marrow transplantation in children: consequences for renal function shortly after and 1 year post-BMT. Bone Marrow Transplant. 1998; 22:559–564.

12. Esiashvili N, Chiang KY, Hasselle MD, Bryant C, Riffenburgh RH, Paulino AC. Renal toxicity in children undergoing total body irradiation for bone marrow transplant. Radiother Oncol. 2009; 90:242–246.

13. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004; 114:2 Suppl 4th Report. 555–576.

14. Shapiro DJ, Hersh AL, Cabana MD, Sutherland SM, Patel AI. Hypertension screening during ambulatory pediatric visits in the United States, 2000-2009. Pediatrics. 2012; 130:604–610.

15. Lo JC, Sinaiko A, Chandra M, et al. Prehypertension and hypertension in community-based pediatric practice. Pediatrics. 2013; 131:e415–e424.

16. Boucek MM, Waltz DA, Edwards LB, et al. Registry of the International Society for Heart and Lung Transplantation: ninth official pediatric heart transplantation report--2006. J Heart Lung Transplant. 2006; 25:893–903.

17. Sinha MD, Kerecuk L, Gilg J, Reid CJ. British Association for Paediatric Nephrology. Systemic arterial hypertension in children following renal transplantation: prevalence and risk factors. Nephrol Dial Transplant. 2012; 27:3359–3368.

18. Armenian SH, Sun CL, Vase T, et al. Cardiovascular risk factors in hematopoietic cell transplantation survivors: role in development of subsequent cardiovascular disease. Blood. 2012; 120:4505–4512.

19. Miller LW. Cardiovascular toxicities of immunosuppressive agents. Am J Transplant. 2002; 2:807–818.

20. Roche SL, Kaufmann J, Dipchand AI, Kantor PF. Hypertension after pediatric heart transplantation is primarily associated with immunosuppressive regimen. J Heart Lung Transplant. 2008; 27:501–507.

21. Panoulas VF, Douglas KM, Stavropoulos-Kalinoglou A, et al. Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology (Oxford). 2008; 47:72–75.

22. Hingorani SR, Guthrie K, Batchelder A, et al. Acute renal failure after myeloablative hematopoietic cell transplant: incidence and risk factors. Kidney Int. 2005; 67:272–277.

23. Ventura HO, Mehra MR, Stapleton DD, Smart FW. Cyclosporine-induced hypertension in cardiac transplantation. Med Clin North Am. 1997; 81:1347–1357.

24. Izumi N, Furukawa T, Sato N, et al. Risk factors for acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: retrospective analysis of 73 patients who received cyclosporin A. Bone Marrow Transplant. 2007; 40:875–880.

25. Singer DR, Jenkins GH. Hypertension in transplant recipients. J Hum Hypertens. 1996; 10:395–402.

26. Wehbe E, Duncan AE, Dar G, Budev M, Stephany B. Recovery from AKI and short- and long-term outcomes after lung transplantation. Clin J Am Soc Nephrol. 2013; 8:19–25.